SLN (Silence Therapeutics) Additional Paid-In Capital : $-613.07 Mil(As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Additional Paid-In Capital?

Silence Therapeutics's quarterly additional paid-in capital increased from Sep. 2024 ($492.49 Mil) to Dec. 2024 ($609.56 Mil) but then stayed the same from Dec. 2024 ($609.56 Mil) to Mar. 2025 ($-613.07 Mil).

Silence Therapeutics's annual additional paid-in capital increased from Dec. 2022 ($280.60 Mil) to Dec. 2023 ($455.77 Mil) and increased from Dec. 2023 ($455.77 Mil) to Dec. 2024 ($609.56 Mil).

Silence Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Silence Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Additional Paid-In Capital Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

216.59

255.79

280.60

455.77

609.56

Silence Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															455.97	457.95	492.49	609.56	-613.07

Silence Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Silence Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.